Global Anxiety Disorder Market
Market Size in USD Million
CAGR :
% 
USD
11.00 Million
USD
16.25 Million
2021
2029
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 11.00 Million |
 Market Size (Forecast Year) |
USD 16.25 Million |
 CAGR |
% |
| Major Markets Players |
|
Global Anxiety Disorder Market, By Type (Panic Disorder, Agoraphobia, Generalized Anxiety, Social Anxiety, Specific Phobia, Others), Treatment (Medications, Therapy, Others), Patients (Inpatients, Outpatients), Route of Administration (Oral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Anxiety Disorder Market Analysis and Size
The global anxiety disorder market is expected to witness significant growth during the forecast period. The rising prevalence of personality disorders and stress build-up especially in adults, rising awareness programmes worldwide through campaigns & media and increased female adult population. Anxiety is becoming a major concern and with each passing time, it is becoming a serious issue for almost all set of population. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global anxiety disorder market in the forecast period 2022-2029. The expected CAGR of global anxiety disorder market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 11 billion in 2021, and it would grow upto USD 16.25 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Anxiety disorder is complex mental health condition that often required medical and psychiatric assistance. Occasional experience of anxiety is a normal part of life but, people having frequently anxiety with intense, excessive, persistent worry and fear about everyday situations is called as disorders. It starts with repeated episodes of sudden feelings of intense anxiety and fear or terror that reach a peak within minutes called panic attacks.
Anxiety Disorder Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Panic Disorder, Agoraphobia, Generalized Anxiety, Social Anxiety, Specific Phobia, Others), Treatment (Medications, Therapy, Others), Patients (Inpatients, Outpatients), Route of Administration (Oral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Pfizer Inc.(U.S.), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries (Israel), Mitsubishi Chemical Group Corporation (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), AstraZeneca (U.K.), H. Lundbeck A/S (Denmark), Forest Laboratories, Inc (U.S.) |
|
Market Opportunities |
|
Global Anxiety Disorder Market Dynamics
Drivers
- Rising Demand for Oral Drugs
Oral drugs is expected to increase the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
- Launch of New Therapies For Anxiety
The rising prevalence of anxiety globally has boosted the researchers to develop novel therapies for the better improvement of mental health. For instance, Janssen CarePath’s esketamine which is a nasal spray formulation of ketamine called SPRAVATO, was approved by the US FDA which serves as a treatment for mood-related conditions such as anxiety issues, post-traumatic stress disorder (PTSD), and depression. This boost the market growth
Opportunities
- Increase Prevalence of Mental Illness
The increasing prevalence of anxiety disorder market is surely affecting the growth of the market. As per the reports of WHO in 2017, over 300 million people of all age groups globally are suffering from depression, and in that, around 800,000 people die from suicide, and it was found that anxiety disorders and depression are the major cause. Additionally, as per the Anxiety and Depression Association of America, anxiety disorders are witnessed to be the most common mental illness disease in the U.S., which affects around 18% of the population. This boosts the market growth.
- Increasing Demand for Retail Pharmacies
Rise in the number of anxiety disorder drugs being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Development of Complications
Many a times, patients aid in the treatment process themselves and these creates complications. Treatment without proper consultation with the doctor is dangerous and results in negative impact on the patients. All these factors restrict the growth of the market.
- Lack of patient awareness
Lack of awareness about anxiety can serve as a restraining factor for the market. Many people are not aware of the fact that they are suffering from anxiety or depression and tend to ignore it and thus as a result, the patients are deprived of the treatment process. This can hamper the market growth.
This global anxiety disorder market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global anxiety disorder market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Anxiety Disorder Market
The COVID 19 pandemic has affected majority of the population. Most of the people are suffering with anxiety disorders. Huge investments have been made by major market players for the development of anxiety disorder treatment due to the increasing cases of cases. This investment gives rise to growing medication and thus increases the anxiety disorder market size in the global market. COVID-19 has a positive effect on the global anxiety disorder market. The market share for anxiety disorders is also expected to grow furthermore in the coming years.
Global Anxiety Disorder Market Scope
The global anxiety disorder market is segmented on the basis of type, treatment, patients, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Panic Disorder
- Agoraphobia
- Generalized Anxiety
- Social Anxiety
- Specific Phobia
- Others
Treatment
- Medications
- Therapy
- Others
Patients
- Inpatients
- Outpatients
Route of Administration
- Oral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Anxiety Disorder Market Regional Analysis/Insights
The global anxiety disorder market is analysed and market size insights and trends are provided by type, treatment, patients, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global anxiety disorder market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global anxiety disorder market throughout the forecasted period due to rapidly improving health care infrastructure in the region.
North America dominates the market due to increased investment by pharmaceutical industries for the advancement in the treatment and favourable reimbursement scenario.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Anxiety Disorder Market Share Analysis
The global anxiety disorder market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global anxiety disorder market
Key players operating in the global anxiety disorder market include:
- Pfizer Inc.(U.S.)
- Merck KGaA (Germany),
- Sanofi (France)
- Biocare Medical, LLC (U.S.)
- Lilly (U.S.)
- Teva Pharmaceutical Industries (Israel)
- Mitsubishi Chemical Group Corporation (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- AstraZeneca (U.K.)
- H. Lundbeck A/S (Denmark)
- Forest Laboratories, Inc (U.S.)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ANXIETY DISORDER MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ANXIETY DISORDER MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ANXIETY DISORDER MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMOLOGY
6.1 INCIDENCE RATE
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR XX
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.14 CURRENT DEVELOPMENT SCENARIO
11 MARKET OVERVIEW
11.1 DRIVERS
11.2 RESTRAINS
11.3 OPPURTUNITY
11.4 CHALLENGES
12 MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13 R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14 GLOBAL ANXIETY DISORDER MARKET, BY TREATMENT
(NOTE: MARKET VALUE, VOLUME AND ASP ANALYSIS WOULD BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS OF PRODUCT)
14.1 OVERVIEW
14.2 MEDICATION
14.2.1 MEDICATION, BY DRUG CLASS
14.2.1.1. SELECTIVE SEROTONIN REUPTAKE INHIBITORS
14.2.1.1.1. BY TYPE
14.2.1.1.1.1 FLUOXETINE
14.2.1.1.1.2 SERTRALINE
14.2.1.1.1.3 ESCITALOPRAM
14.2.1.1.1.4 PAROXETINE
14.2.1.1.1.5 CITALOPRAM
14.2.1.1.2. BY DISORDER
14.2.1.1.2.1 PANIC DISORDER
14.2.1.1.2.2 SOCIAL ANXIETY DISORDER
14.2.1.1.2.3 GENERAL ANXIETY DISORDER
14.2.1.1.2.4 PHOBIA
14.2.1.1.2.5 PTSD
14.2.1.1.2.6 OCD
14.2.1.1.2.7 OTHERS
14.2.1.2. SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS
14.2.1.2.1. BY TYPE
14.2.1.2.1.1 VENLAFAXINE
14.2.1.2.1.2 DULOXETINE
14.2.1.2.1.3 DESVENLAFAXINE
14.2.1.2.2. BY MODE OF ACTION
14.2.1.2.2.1 IMMEDIATE RELEASED
14.2.1.2.2.2 CONTROLLED RELEASED
14.2.1.2.3. BY DISORDER
14.2.1.2.3.1 PANIC DISORDER
14.2.1.2.3.2 SOCIAL ANXIETY DISORDER
14.2.1.2.3.3 GENERAL ANXIETY DISORDER
14.2.1.2.3.4 PHOBIA
14.2.1.2.3.5 PTSD
14.2.1.2.3.6 OCD
14.2.1.2.3.7 OTHERS
14.2.1.3. BENZODIAZEPINES
14.2.1.3.1. BY TYPE
14.2.1.3.1.1 ALPRAZOLAM
14.2.1.3.1.2 DIAZEPAM
14.2.1.3.1.3 LORAZEPAM
14.2.1.3.1.4 CLONAZEPAM
14.2.1.3.2. BY DISORDER
14.2.1.3.2.1 PANIC DISORDER
14.2.1.3.2.2 SOCIAL ANXIETY DISORDER
14.2.1.3.2.3 GENERAL ANXIETY DISORDER
14.2.1.3.2.4 PHOBIA
14.2.1.3.2.5 PTSD
14.2.1.3.2.6 OCD
14.2.1.3.2.7 OTHERS
14.2.1.4. ANTIDEPRESSANTS
14.2.1.4.1. BY TYPE
14.2.1.4.1.1 AMITRIPTYLINE
14.2.1.4.1.2 NORTRIPTYLINE
14.2.1.4.1.3 IMIPRAMMINE
14.2.1.4.1.4 DESIPRAMINE
14.2.1.4.2. BY DISORDER
14.2.1.4.2.1 PANIC DISORDER
14.2.1.4.2.2 SOCIAL ANXIETY DISORDER
14.2.1.4.2.3 GENERAL ANXIETY DISORDER
14.2.1.4.2.4 PHOBIA
14.2.1.4.2.5 PTSD
14.2.1.4.2.6 OCD
14.2.1.4.2.7 OTHERS
14.2.1.5. BETA-BLOCKERS
14.2.1.5.1. BY TYPE
14.2.1.5.1.1 PROPANOLOL
14.2.1.5.1.2 ATENOLOL
14.2.1.5.1.3 METOPROLOL
14.2.1.5.1.4 NADOLOL
14.2.1.5.2. BY DISORDER
14.2.1.5.2.1 PANIC DISORDER
14.2.1.5.2.2 SOCIAL ANXIETY DISORDER
14.2.1.5.2.3 GENERAL ANXIETY DISORDER
14.2.1.5.2.4 PHOBIA
14.2.1.5.2.5 PTSD
14.2.1.5.2.6 OCD
14.2.1.5.2.7 OTHERS
14.2.1.6. OTHERS
14.2.1.6.1. GABAERGIC
14.2.1.6.1.1 PREGABALIN
14.2.1.6.1.2 GABAPENTIN
14.2.1.6.2. AZAPIRONES
14.2.1.6.3. ANTIPSYCHOTICS
14.2.1.6.3.1 TRIFLUPERAZINE
14.2.1.6.3.2 OLANZEPINE
14.2.1.6.3.3 QUETIAPINE
14.2.1.6.4. ANTICONVULSANTS
14.3 THERAPY
14.3.1 BY TYPE
14.3.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
14.3.1.1.1. COGNITIVE RESTRUCTURING
14.3.1.1.2. EXPOSURE THERAPY
14.3.1.1.3. OCCUPATIONAL THERAPY
14.3.1.2. BIOFEEDBACK THERAPY
14.3.1.2.1. ELECTROMYOGRAPHY-BASED BIOFEEDBACK THERAPY
14.3.1.2.2. THERMAL BIOFEEDBACK THERAPY
14.3.1.2.3. NEUROFEEDBACK THERAPY
14.3.1.3. VIRTUAL REALITY THERAPY
14.3.2 BY OFFERING
14.3.2.1. PHYSICAL CONSULATION
14.3.2.2. ONLINE THERAPY
15 GLOBAL ANXIETY DISORDER MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 CAPSULE
15.2.2 TABLET
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 INTRAVENOUS
15.3.2 SUB-CUTANEOUS
15.4 OTHERS
16 GLOBAL ANXIETY DISORDER MARKET, BY DOSAGE
16.1 OVERVIEW
16.2 MONO-THERAPY
16.3 COMBINATION THERAPY
17 GLOBAL ANXIETY DISORDER MARKET, BY DRUG TYPE
17.1 OVERVIEW
17.2 BRANDED
17.2.1 CYMBALTA
17.2.2 EFFEXOR
17.2.3 ELAVIL
17.2.4 SINEQUAN
17.2.5 XANAX
17.2.6 ATIVAN
17.2.7 KLONOPIN
17.2.8 CELEXA
17.2.9 LEXAPRO
17.2.10 ZOLOFT
17.2.11 OTHERS
17.3 GENERICS
18 GLOBAL ANXIETY DISORDER MARKET, BY TYPE
18.1 OVERVIEW
18.2 PANIC DISORDER
18.2.1 MEDICATION
18.2.2 THERAPY
18.3 GENERALIZED ANXIETY DISORDER
18.3.1 MEDICATION
18.3.2 THERAPY
18.4 SOCIAL ANXIETY DISORDER
18.4.1 MEDICATION
18.4.2 THERAPY
18.5 PHOBIA
18.5.1 MEDICATION
18.5.2 THERAPY
18.6 POST-TRAUMATIC STRESS DISORDER
18.6.1 MEDICATION
18.6.2 THERAPY
18.7 OBSESSIVE-COMPULSIVE DISORDER
18.7.1 MEDICATION
18.7.2 THERAPY
19 GLOBAL ANXIETY DISORDER MARKET, BY PATIENT
19.1 OVERVIEW
19.2 INPATIENT
19.3 OUTPATIENTS
20 GLOBAL ANXIETY DISORDER MARKET, BY AGE GROUP
20.1 OVERVIEW
20.2 PEDIATRIC
20.3 ADULT
20.4 GERIATRIC
21 GLOBAL ANXIETY DISORDER MARKET, BY END USER
21.1 OVERVIEW
21.2 HOSPITALS
21.3 SPECIALTY CLINIC
21.4 REHABILITATION CENTER
21.5 HOMECARE
21.6 OTHERS
22 GLOBAL ANXIETY DISORDER MARKET, BY DISTRIBUTION CHANNEL
22.1 OVERVIEW
22.2 HOSPITAL PHARMACY
22.3 ONLINE PHARMACY
22.4 RETAIL PHARMACY
22.5 OTHERS
23 GLOBAL ANXIETY DISORDER MARKET, SWOT AND DBMR ANALYSIS
24 GLOBAL ANXIETY DISORDER MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.2 COMPANY SHARE ANALYSIS: EUROPE
24.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.4 MERGERS & ACQUISITIONS
24.5 NEW PRODUCT DEVELOPMENT & APPROVALS
24.6 EXPANSIONS
24.7 REGULATORY CHANGES
24.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL ANXIETY DISORDER MARKET, BY GEOGRAPHY
GLOBAL ANXIETY DISORDER MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
25.1 NORTH AMERICA
25.1.1 U.S.
25.1.2 CANADA
25.1.3 MEXICO
25.2 EUROPE
25.2.1 GERMANY
25.2.2 FRANCE
25.2.3 U.K.
25.2.4 HUNGARY
25.2.5 LITHUANIA
25.2.6 AUSTRIA
25.2.7 IRELAND
25.2.8 NORWAY
25.2.9 POLAND
25.2.10 ITALY
25.2.11 SPAIN
25.2.12 RUSSIA
25.2.13 TURKEY
25.2.14 NETHERLANDS
25.2.15 SWITZERLAND
25.2.16 REST OF EUROPE
25.3 ASIA-PACIFIC
25.3.1 JAPAN
25.3.2 CHINA
25.3.3 SOUTH KOREA
25.3.4 INDIA
25.3.5 AUSTRALIA
25.3.6 SINGAPORE
25.3.7 THAILAND
25.3.8 MALAYSIA
25.3.9 INDONESIA
25.3.10 PHILIPPINES
25.3.11 VIETNAM
25.3.12 REST OF ASIA-PACIFIC
25.4 SOUTH AMERICA
25.4.1 BRAZIL
25.4.2 ARGENTINA
25.4.3 PERU
25.4.4 COLOMBIA
25.4.5 VENEZUELA
25.4.6 REST OF SOUTH AMERICA
25.5 MIDDLE EAST AND AFRICA
25.5.1 SOUTH AFRICA
25.5.2 SAUDI ARABIA
25.5.3 UAE
25.5.4 EGYPT
25.5.5 KUWAIT
25.5.6 ISRAEL
25.5.7 REST OF MIDDLE EAST AND AFRICA
25.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
26 GLOBAL ANXIETY DISORDER MARKET, COMPANY PROFILE
26.1 PFIZER INC.
26.1.1 COMPANY OVERVIEW
26.1.2 REVENUE ANALYSIS
26.1.3 GEOGRAPHIC PRESENCE
26.1.4 PRODUCT PORTFOLIO
26.1.5 RECENT DEVELOPMENTS
26.2 MERCK KGAA
26.2.1 COMPANY OVERVIEW
26.2.2 REVENUE ANALYSIS
26.2.3 GEOGRAPHIC PRESENCE
26.2.4 PRODUCT PORTFOLIO
26.2.5 RECENT DEVELOPMENTS
26.3 SANOFI
26.3.1 COMPANY OVERVIEW
26.3.2 REVENUE ANALYSIS
26.3.3 GEOGRAPHIC PRESENCE
26.3.4 PRODUCT PORTFOLIO
26.3.5 RECENT DEVELOPMENTS
26.4 LIFECARE NEURO PRODUCTS LTD.
26.4.1 COMPANY OVERVIEW
26.4.2 REVENUE ANALYSIS
26.4.3 GEOGRAPHIC PRESENCE
26.4.4 PRODUCT PORTFOLIO
26.4.5 RECENT DEVELOPMENTS
26.5 WEEFSEL PHARMA
26.5.1 COMPANY OVERVIEW
26.5.2 REVENUE ANALYSIS
26.5.3 GEOGRAPHIC PRESENCE
26.5.4 PRODUCT PORTFOLIO
26.5.5 RECENT DEVELOPMENTS
26.6 LILLY
26.6.1 COMPANY OVERVIEW
26.6.2 REVENUE ANALYSIS
26.6.3 GEOGRAPHIC PRESENCE
26.6.4 PRODUCT PORTFOLIO
26.6.5 RECENT DEVELOPMENTS
26.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
26.7.1 COMPANY OVERVIEW
26.7.2 REVENUE ANALYSIS
26.7.3 GEOGRAPHIC PRESENCE
26.7.4 PRODUCT PORTFOLIO
26.7.5 RECENT DEVELOPMENTS
26.8 BRISTOL-MYERS SQUIBB COMPANY
26.8.1 COMPANY OVERVIEW
26.8.2 REVENUE ANALYSIS
26.8.3 GEOGRAPHIC PRESENCE
26.8.4 PRODUCT PORTFOLIO
26.8.5 RECENT DEVELOPMENTS
26.9 SUN PHARMACEUTICAL INDUSTRIES LTD.
26.9.1 COMPANY OVERVIEW
26.9.2 REVENUE ANALYSIS
26.9.3 GEOGRAPHIC PRESENCE
26.9.4 PRODUCT PORTFOLIO
26.9.5 RECENT DEVELOPMENTS
26.1 SAHAJANAND HEALTH CARE
26.10.1 COMPANY OVERVIEW
26.10.2 REVENUE ANALYSIS
26.10.3 GEOGRAPHIC PRESENCE
26.10.4 PRODUCT PORTFOLIO
26.10.5 RECENT DEVELOPMENTS
26.11 ASTRAZENECA
26.11.1 COMPANY OVERVIEW
26.11.2 REVENUE ANALYSIS
26.11.3 GEOGRAPHIC PRESENCE
26.11.4 PRODUCT PORTFOLIO
26.11.5 RECENT DEVELOPMENTS
26.12 H. LUNDBECK A/S
26.12.1 COMPANY OVERVIEW
26.12.2 REVENUE ANALYSIS
26.12.3 GEOGRAPHIC PRESENCE
26.12.4 PRODUCT PORTFOLIO
26.12.5 RECENT DEVELOPMENTS
26.13 DIVINE SAVIOR PRIVATE LIMITED
26.13.1 COMPANY OVERVIEW
26.13.2 REVENUE ANALYSIS
26.13.3 GEOGRAPHIC PRESENCE
26.13.4 PRODUCT PORTFOLIO
26.13.5 RECENT DEVELOPMENTS
26.14 CONSERN PHARMA LIMITED.
26.14.1 COMPANY OVERVIEW
26.14.2 REVENUE ANALYSIS
26.14.3 GEOGRAPHIC PRESENCE
26.14.4 PRODUCT PORTFOLIO
26.14.5 RECENT DEVELOPMENTS
26.15 VIATRIS INC.
26.15.1 COMPANY OVERVIEW
26.15.2 REVENUE ANALYSIS
26.15.3 GEOGRAPHIC PRESENCE
26.15.4 PRODUCT PORTFOLIO
26.15.5 RECENT DEVELOPMENTS
26.16 ABBVIE INC.
26.16.1 COMPANY OVERVIEW
26.16.2 REVENUE ANALYSIS
26.16.3 GEOGRAPHIC PRESENCE
26.16.4 PRODUCT PORTFOLIO
26.16.5 RECENT DEVELOPMENTS
26.17 SOLCO HEALTHCARE.
26.17.1 COMPANY OVERVIEW
26.17.2 REVENUE ANALYSIS
26.17.3 GEOGRAPHIC PRESENCE
26.17.4 PRODUCT PORTFOLIO
26.17.5 RECENT DEVELOPMENTS
26.18 GSK PLC.
26.18.1 COMPANY OVERVIEW
26.18.2 REVENUE ANALYSIS
26.18.3 GEOGRAPHIC PRESENCE
26.18.4 PRODUCT PORTFOLIO
26.18.5 RECENT DEVELOPMENTS
26.19 F. HOFFMANN-LA ROCHE LTD
26.19.1 COMPANY OVERVIEW
26.19.2 REVENUE ANALYSIS
26.19.3 GEOGRAPHIC PRESENCE
26.19.4 PRODUCT PORTFOLIO
26.19.5 RECENT DEVELOPMENTS
26.2 JOHNSON & JOHNSON
26.20.1 COMPANY OVERVIEW
26.20.2 REVENUE ANALYSIS
26.20.3 GEOGRAPHIC PRESENCE
26.20.4 PRODUCT PORTFOLIO
26.20.5 RECENT DEVELOPMENTS
26.20.6
27 RELATED REPORTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
